## Research Compliance Activity and Turn-Around-Time (TAT) Summary Report Fiscal Year 2023 (7/1/2022 to 6/30/2023)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - Bloomington											
	Q1 TAT		Q2 TAT		Q3 TAT		Q4	TAT			
	Mean	Median	Mean	Median	Mean	Median	Mean	Median			
Full Board											
New Studies - Full Board (to review)	10.0	10.0									
New Studies - Full Board (to approval)	85.0	85.0									
Exempt											
New Studies - Exempt (to determination)	32.3	21.0									
Amendments											
Amendments - Minor	4.8	6.8									
Amendments - Major	25.3	24.0									

<sup>\*</sup>Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

	Q1 (Jul-Sep)			Q2 (Oct-Dec)				Q3 (Jan-Mai	r)	Q4 (Apr-Jun)		
			Throughput/			Throughput/			Throughput/			Throughput/
Area Activities/Throughput (T)	Received	Completed	% Backlogged	Received	Completed	% Backlogged	Received	Completed	% Backlogged	Received	Completed	% Backlogged
New Studies - Full Board	0	1	1			n/a			n/a			n/a
New Studies - Exempt	3	3	0			n/a			n/a			n/a
Amendments - Minor	53	61	8			n/a			n/a			n/a
Amendments - Major	5	6	1			n/a			n/a			n/a
Continuing Reviews	15	22	7			n/a			n/a			n/a
TOTAL	76	93	17 (-22.4%)	0	0		0	0		0	0	

	Q1	Q2	Q3	Q4	FY
Area Training Activities	(Jul-Sep)	(Oct-Dec)	(Jan-Mar)	(Apr-Jun)	TOTALS
Presentations (# of events)	0				0

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0				0
30 Day OBA Report	0				0
Lab Accident/Injury/Exposure	0				0

Reporting Agency: NIH Office of Biotechnology Activites (OBA)

## Research Compliance Activity and Turn-Around-Time (TAT) Summary Report Fiscal Year 2023 (7/1/2022 to 6/30/2023)

Institutional Biosafety Committee (IBC) - IU Bloomington																
	Q1 TAT				Q2 TAT			Q3 TAT				Q4 TAT				
	Review	Review	Total TAT	Total TAT	Review	Review	Total TAT	Total TAT	Review	Review	Total TAT	Total TAT	Review	Review	Total TAT	Total TAT
	Mean	Median	Mean	Median												
Initial																
Full Committee					33	33	40	40	28	28	30	30				
Biosafety Officer Review					35	35	43	43	25	17	33	20				
Amended																
Full Committee					n/a	n/a	n/a	n/a	43	39	45	43				
Biosafety Officer Review					10	7	13	9	10	8	15	10				
Renewed/Amended																
Full Committee					32	31	34	33	87	87	100	100				
Biosafety Officer Review					14	. 9	20	11	16	13	27	22				
Renewed		•	•				•		•	•						
Full Committee					n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Biosafety Officer Review					C	0	0	0	C	0	0	0				

				00						24			
		Q1		Q2			Q3			Q4			
Area Activities/Throughput (T)	Received	Completed	Throughput										
Initial Full Committee				1	1	0	4	2	-2			0	
Initial Biosafety Officer Review				3	1	-2	. 2	2	0			0	
Amended Full Committee				1	0	-1	. 3	2	-1			0	
Amended Biosafety Officer Review				19	18	-1	. 25	25	0			0	
Renewed/Amended Full Committee				7	4	-3	1	0	-1			0	
Renewed/Amended Biosafety Officer													
Review				36	28	-8	28	23	-5			0	
Renewed Full Committee				n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	
Renewed Biosafety Officer Review				2	2	0	1	1	0			0	
TOTAL				69	54	-15	64	55	-9	0	0	0	

					FY
Reportable Events/Activities	Q1	Q2	Q3	Q4	TOTALS
Immediate OBA Report	0	0	0		0
30 Day OBA Report	0	1	0		1
Lab Accident/Injury/Exposure	0	0	1		1

Reporting Agency: NIH Office of Biotechnology Activites (OBA)

FY2023 Q1 metrics are from a legacy system.